直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Webinar

Making the Biosimilar Business Case—Exploring the Interface Between Economics and Patent Law

January 24, 2017

Webinar

View Webinar

This first webcast of our series will explore both the economic market factors of the biosimilar world and patent strategies, and how they impact target selection for biologics and biosimilars. In contrast to the development of generic small molecules, it has been reported that it takes seven to eight years to develop a biosimilar at a cost of between $100 million and $250 million. The identification of targets requires detailed analyses of the marketplace, patent portfolios, long-term strategies for optimizing and navigating patent portfolios, and technical and regulatory issues in developing a biologic or biosimilar.

The panel will discuss factors for consideration in strategic selection and protection of biologic products, including:

  • The scope of patent protection available for biologic products
  • The impact of differences in patent protection in the United States and Europe
  • Deciding between patent and trade secret protection
  • Research, manufacturing and supply considerations, such as safe harbor protection, the ease of potential design-arounds, and potential infringement liability when a patented combination is done outside of the United States or an imported product is made by patented process performed outside of the United States
  • Considerations for the use of post-grant proceedings before the United States Patent and Trademark Office and district court litigation to clear the patent thicket, including the alternative, sequential, or concurrent timing of those proceedings

This webinar is the first in Finnegan’s 2017 “Biologics and Biosimilars: The Big Picture.”

Moderator: 
Basil “Bill” J. Lewris

Speakers: 
Leslie A. McDonell 
Linda A. Wadler

Date:

Tuesday, January 24, 2017

Time:

10:00 - 11:00 a.m. PST
1:00 - 2:00 p.m. EST

Scheduling Conflict? Finnegan records all hosted webinars. To view the recorded program, simply register for the webinar and you will receive an access link shortly after the live program is complete.

Downloadable Files

  • Webinar: Making the Biosimilar Business Case—Exploring the Interface Between Economics and Patent Law

Related Practices

智財權申請及組合管理

營業秘密

Related Industries

生物藥品

Related Insights

Conference

IAM Live: Navigating the UPC 2026

November 3, 2026

Paris

Conference

4th Global Patent Litigation FORUM

October 29, 2026

Munich

Conference

2026 AIPLA Annual Meeting

October 29-31, 2026

Washington, DC

Conference

2026 EDTX Bench Bar Conference

October 28-30, 2026

Fort Worth

Conference

ChIPs Global Summit 2026

October 21-23, 2026

Los Angeles

Hybrid Conference

Intellectual Property Law Institute 2026 – California

October 19-20, 2026

San Francisco

Hybrid Conference

Intellectual Property Law Institute 2026 – New York

September 28-29, 2026

New York

Conference

2026 IPO Annual Meeting

September 27-29, 2026

Toronto

Conference

IAM Live: SEP Summit Global 2026

September 9-10, 2026

London

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP